АДЕМЕТИОНИН В ЛЕЧЕНИИ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ
https://doi.org/10.21518/2079-701X-2017-15-104-111
Аннотация
В статье представлены современные положения о патогенезе неалкогольной жировой болезни печени (НАЖБП), а также краткий обзор методов терапии. Рассмотрены основные механизмы антиоксидантного действия адеметионина в лечении НАЖБП, анализ доказательной базы его эффективности. Приводятся клинические наблюдения, свидетельствующие в пользу положительного влияния применения адеметионина у больных НАЖБП.
Об авторах
А. В. Полухина
Московский клинический научно-практический центр им. А.С. Логинова Департамента здравоохранения г. Москвы Центрального
научно-исследовательского института гастроэнтерологии
Россия
Россия
Е. В. Винницкая
Московский клинический научно-практический центр им. А.С. Логинова Департамента здравоохранения г. Москвы Центрального
научно-исследовательского института гастроэнтерологии
Россия
д.м.н
Россия
д.м.н
Ю. Г. Сандлер
Московский клинический научно-практический центр им. А.С. Логинова Департамента здравоохранения г. Москвы Центрального
научно-исследовательского института гастроэнтерологии
Россия
Россия
к.м.н.
Т. Ю. Хайменова
Московский клинический научно-практический центр им. А.С. Логинова Департамента здравоохранения г. Москвы Центрального
научно-исследовательского института гастроэнтерологии
Россия
Россия
к.м.н
Список литературы
1. Smith BW & Adams LA. Non-alcoholic fatty liver disease. Critical Reviews in Clinical Laboratory Sciences, 2011, 8: 97-113.
2. Бакулин И.Г., Сандлер Ю.Г., Винницкая Е.В., Кейян В.А., Драпун С.В. Оценка стеатоза печени с помощью неинвазивного метода: миф или реальность? Доктор.Ру. Гастроэнтерология, 2015, 12: 57-64.
3. Бакулин И.Г., Сандлер Ю.Г., Кейян В.А., Ротин Д.Л. Новый неинвазивный метод оценки стеатоза при хронических заболеваниях печени. Терапевтический архив, 2016, 88(2): 49-57.
4. Ивашкин В.Т., Драпкина О.М., Шульпекова Ю.О. Диагностика и лечение неалкогольной жировой болезни печени (методические рекомендации). М.: «Издательский дом “М-Вести”», 2009: 20.
5. Павлов Ч.С., Глушенков Д.В., Ивашкин В.Т. Диагностика неалкогольной жировой болезни печени с использованием методов неинвазивного скрининга населения. Врач, 2010, 12: 13-19.
6. Мехтиев С.Н., Гриневич В.Б., Кравчук Ю.А., Бращенкова А.В. Неалкогольная жировая болезнь печени: клиника, диагностика и лечение. Лечащий Врач, 2008, 2.
7. Ahmed MH, Byrne ChD. Non-alcoholic steatohepatitis. The Metabolic Syndrome, 2005: 279-305.
8. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology, 2004, 40: 1387–1395.
9. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am. J. Physiol. Endocrinol. Metab., 2005, 288: 462–468.
10. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol, 2013, 58: 593–608.
11. Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology, 2004, 40: 820–826.
12. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med, 2011, 43: 17–49.
13. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med, 2011, 43: 51–62.
14. Compare D, Coccoli P, Rocco A et al. Gut-liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis, 2012, 22: 471–476.
15. Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K. Gut microbiota and non-alcoholic fatty liver disease: new insights. J. Clin Microbiol Infect, 2013, 19: 338–348.
16. Day CP. Genetic and environmental susceptibility to non-alcoholic fatty liver disease. Dig Dis, 2010, 28(1): 55–60.
17. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroentero-logy, and the American Gastroenterological Association. Hepatology, 2012: 18-23.
18. Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, Modi A, Nagabhyru P, Sumner AE, Liang TJ, Hoofnagle JH. Clinical trial: pilot study of metformin for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Therapeut, 2009, 29: 172–82.
19. Van Wagner LB, Koppe SW, Brunt EM, Gottstein J, Gardikiotes K, Green RM, Rinella ME.Pentoxifylline for the treatment of nonalcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol, 2011, 10: 277–86.
20. LaBrecque DR, Abbas Z, Anania F, Ferenci P, Khan AG, Goh KL, Hamid SS, Isakov V, Lizarzabal M, Penaranda MM, Ramos JF, Sarin S, Stimac D, Thomson AB, Umar M, Krabshuis J, LeMair A. Review Team. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol, 2014, 48: 467–73.
21. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E, NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet, 2015, 385: 956-65.
22. Silveira MG, Lindor KD. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis. Expert Opin Pharmacother, 2014, 15: 365–72.
23. Mato JM, Martinez-Chantar ML, Lu SC. S-adenosylmethionine metabolism and liver disease. Ann Hepatol, 2013, 12: 183–9.
24. Lu SC, Mato JM. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev, 2012, 92: 1515–42.
25. Li Z, Agellon LB, Allen TM, Umeda M, Jewell L, Mason A, Vance DE. The ratio of phosphatidyl-choline to phosphatidylethanolamine influences membrane integrity and steatohepati-tis. Cell Metab, 2006, 3: 321–31.
26. Vance DE. Physiological roles of phosphatidylethanolamine N-methyltransferase. Biochim Biophys Acta, 2013, 1831: 626–32.
27. Cano A, Buque X, Martinez-Una M, Aurrekoetxea I, Menor A, Garcia-Rodriguez JL, Lu SC, Martinez-Chantar ML, Mato JM, Ochoa B, Aspichueta P. Methionine adenosyltransferase 1A gene deletion disrupts hepatic very low-density lipoprotein assembly in mice. Hepatology, 2011, 54: 1975–86.
28. Walker AK, Jacobs RL, Watts JL, Rottiers V, Jiang K, Finnegan DM, Shioda T, Hansen M, Yang F, Niebergall LJ, Vance DE, Tzoneva M, Hart AC, Naar AM. A conserved SREBP-1/phosphatidyl-choline feedback circuit regulates lipogenesis in metazoans. Cell, 2011, 147: 840–52.
29. Caballero F, Fernandez A, Matias N, Martinez L, Fucho R, Elena M, Caballeria J, Morales A, Fernandez-Checa JC, Garcia-Ruiz C. Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-L-methionine and glutathione. J Biol Chem, 2010, 285: 18528–36.
30. Chawla RK, Bonkovsky HL, Galambos JT. Biochemistry and pharmacology of S-adenosyl-L-methionine and rationale for its use in liver disease. Drugs, 1990, 40(Suppl 3): 98–110.
31. Fu S, Yang L, Li P, Hofmann O, Dicker L, Hide W, Lin X, Watkins SM, Ivanov AR, Hotamisligil GS.Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. Nature, 2011, 473: 528–31.
32. Friedel HA, Goa KL, Benfield P. S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs, 1989, 38: 389–416.
33. Vendemiale G, Altomare E, Trizio T, Le Grazie C, Di Padova C, Salerno MT, Carrieri V, Albano O.Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol, 1989, 24: 407–15.
34. Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol, 2012, 57: 1097–109.
35. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol, 2001, 96: 2711–17.
36. Abdelmalek MF, Sanderson SO, Angulo P, Soldevila-Pico C, Liu C, Peter J, Keach J, Cave M, Chen T, McClain CJ, Lindor KD. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology, 2009, 50: 1818–26.
37. Medici V, Virata MC, Peerson JM, Stabler SP, French SW, Gregory JF, 3rd, Albanese A, Bowlus CL, Devaraj S, Panacek EA, Richards JR, Halsted CH. S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial. Alcohol Clin Exp Res, 2011, 35: 1960–5.
38. Oz HS, Im HJ, Chen TS, de Villiers WJ, McClain CJ. Glutathione-enhancing agents protect against steatohepatitis in a dietary model. J Biochem Mol Toxicol, 2006, 20: 39–47.
39. Chawla RK, Watson WH, Eastin CE, Lee EY, Schmidt J, McClain CJ. S-adenosylmethionine deficiency and TNF-alpha in lipopolysaccha-ride-induced hepatic injury. Am J Physiol, 1998, 275: G125–9.
40. Fiorelli G. S-adenosylmethionine in the treatment of intrahepatic cholestasis of chronic liver disease: a field trial. Curr Ther Res Clin Exp, 1999, 60(6):335–48.
41. Manzillo G, Piccinino F, Surrenti C, Frezza M, Giudici GA, Grazie DCL. Multicentre Double-Blind Placebo-Controlled Study of Intravenous and Oral S-Adenosyl-L-Methionine (SAMe) in Cholestatic Patients with Liver Disease. Drug Invest, 1992 Jan 1, 4(4): 90–100.
42. Hardy M, Coulter I, Morton SC et al. S-Adenosyl-L-Methionine for Treatment of Depression, Osteo arthritis, and Liver Disease. Evidence Report/Tech nology Assessment Number 64 (Prepared by Southern California Evidence-based Practice Center under Contract No. 290-97-0001). AHRQ Publication No. 02-E034. Rockville, MD: Agency for Healthcare Research and Quality. October 2002.
Рецензия
Для цитирования:
Полухина АВ, Винницкая ЕВ, Сандлер ЮГ, Хайменова ТЮ. АДЕМЕТИОНИН В ЛЕЧЕНИИ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ. Медицинский Совет. 2017;(15):104-111. https://doi.org/10.21518/2079-701X-2017-15-104-111
For citation:
Polukhina AV, Vinnitskaya EV, Sandler YG, Khaimenova TY. ADEMETHIONINE IN THERAPY OF NON-ALCOHOLIC FATTY LIVER DISEASE. Meditsinskiy sovet = Medical Council. 2017;(15):104-111. (In Russ.) https://doi.org/10.21518/2079-701X-2017-15-104-111
Просмотров:
923
Послать статью по эл. почте 